Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.060x

Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.34 Million ≈ $6.49 Million USD) by net assets (CN¥735.65 Million ≈ $107.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hainan Huluwa Pharmaceutical Group Co Lt (605199) balance sheet quality index to measure how much of total assets are equity-financed.

Hainan Huluwa Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 605199 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Bsm Chemical Co Ltd SHE:300796	0.056x
SF Urban Properties AG SW:SFPN	-0.044x
XinJiang Beiken Energy Engineering Stock Co Ltd SHE:002828	0.068x
Boston Omaha Corp NYSE:BOC	0.011x
Anhui Shiny Electronic Technology Company Limited SHE:300956	N/A
Selectirente PA:SELER	0.019x
Jiayuan Science and Technology Co.Ltd. SHE:301117	N/A
PetroChina Jinhong Energy Investment Co Ltd SHE:000669	0.575x

Annual Cash Flow Conversion Efficiency for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Hainan Huluwa Pharmaceutical Group Co Lt.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥458.02 Million ≈ $67.02 Million	CN¥136.85 Million ≈ $20.03 Million	0.299x	+248.94%
2024-12-31	CN¥743.28 Million ≈ $108.77 Million	CN¥-149.12 Million ≈ $-21.82 Million	-0.201x	-923.26%
2023-12-31	CN¥1.16 Billion ≈ $169.65 Million	CN¥28.25 Million ≈ $4.13 Million	0.024x	-89.64%
2022-12-31	CN¥1.02 Billion ≈ $148.57 Million	CN¥238.71 Million ≈ $34.93 Million	0.235x	+113.48%
2021-12-31	CN¥930.52 Million ≈ $136.16 Million	CN¥102.48 Million ≈ $15.00 Million	0.110x	+2958.79%
2020-12-31	CN¥916.48 Million ≈ $134.11 Million	CN¥3.30 Million ≈ $482.88K	0.004x	-98.40%
2019-12-31	CN¥643.94 Million ≈ $94.23 Million	CN¥144.51 Million ≈ $21.15 Million	0.224x	+326.73%
2018-12-31	CN¥604.61 Million ≈ $88.47 Million	CN¥31.80 Million ≈ $4.65 Million	0.053x	-79.46%
2017-12-31	CN¥351.38 Million ≈ $51.42 Million	CN¥89.96 Million ≈ $13.16 Million	0.256x	-49.28%
2016-12-31	CN¥128.69 Million ≈ $18.83 Million	CN¥64.96 Million ≈ $9.51 Million	0.505x	--

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic

Market Cap

$351.88 Million

CN¥2.40 Billion CNY

Market Cap Rank

#14061 Global

#4192 in China

Share Price

CN¥6.01

Change (1 day)

+3.80%

52-Week Range

CN¥5.19 - CN¥10.20

All Time High

CN¥48.21